Literature DB >> 650752

The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading.

H A Gilbert, J L Logan, A R Kagan, H A Friedman, J K Cove, M Fox, T M Muldoon, Y W Lonni, J H Rowe, J F Cooper, H Nussbaum, P Chan, A Rao, A Starr.   

Abstract

Between 1950 and 1965, 365 patients were treated for transitional cancer of the bladder at our hospitals. A retrospective study was done, using clinical records and a histopathologic review to determine the long-term natural history of this population when treated conservatively. The natural history of 3 separate patient populations was discovered, based solely on the grading of the transurethrally resected fragments. Based on the grade on initial presentation these patients were divided into grades I, II and III. Of the patients 5 per cent in grade I, 16 per cent in grade II, 28 to 35 per cent in grade III not involving muscle and 83 per cent in grade III involving muscle died of bladder cancer. Ninety-seven patients (26 per cent) died of bladder cancer, 110 (31 per cent) died of other causes and 158 (43 per cent) have been alive more than 5 years (104 more than 10 years). Grade I tumors that progressed to a higher grade did so within 2 years of the initial diagnosis. Of the bladder cancer deaths 83 per cent occurred within 2 years of the initial diagnosis. Of 64 patients dying more than 5 years after presentation only 7 died of bladder cancer.

Entities:  

Mesh:

Year:  1978        PMID: 650752     DOI: 10.1016/s0022-5347(17)57526-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Cystoscopy in bladder cancer.

Authors:  S Prescott; D A Tolley
Journal:  BMJ       Date:  1994-03-12

2.  Bladder cancer.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-28

3.  Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer.

Authors:  F Pagès; S Lebel-Binay; A Vieillefond; L Deneux; M Cambillau; O Soubrane; B Debré; D Tardy; J-L Romet Lemonne; J-P Abastado; W-H Fridman; N Thiounn
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 4.  Invasiveness of transformed bladder epithelial cells.

Authors:  J F Kieler
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 5.  Superficial bladder carcinoma. Factors affecting the natural history.

Authors:  J M Fitzpatrick
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

6.  Intravesical administration of tumor-associated monoclonal antibody AUA1 in transitional cell carcinoma of the bladder: a study of biodistribution.

Authors:  J Zorzos; D V Skarlos; A A Epenetos; D Pectasides; P Koutsioumba; J Elemenoglou; A Bakiras; M Likourinas; K Dimopoulos
Journal:  Urol Res       Date:  1993

7.  The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.

Authors:  J C Angulo; J I Lopez; N Flores; J D Toledo
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Prognostic factors in superficial bladder cancer.

Authors:  H A Ozen; A Akdaş; T Alkibay; U Altuğ; D Remzi
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

9.  Karyometry in recurrent superficial transitional cell tumors of the bladder.

Authors:  H G van der Poel; R D van Caubergh; M E Boon; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1992

10.  A follow-up study of urinary bladder patients tested for tumour-related lymphocyte-mediated cytotoxicity.

Authors:  A Larsson; I Näslund; M Troye
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.